Türkiye'nin Hatay İlinde Orak Hücre Hastalığı Olan Hastalarda COVİD-19'un Klinik Sonuçları

Amaç:SARS-COV-2’nin sebep olduğu covid-19 enfeksiyonu özellikle solunum sistemi tutulumu ve koagülopati nedeniyle mortal olarak seyredebilmektedir.Benzer şekilde orak hücre hastalarında da solunum sistemi ve koagülopati ilişkili ölüm mortalitenin önemli sebepleri arasında yer almaktadır.Yapılmış olan çalışmalarda covid-19 enfeksiyonunun orak hücre hastalarındaki mortalite oranları ile ilgili çelişkili sonuçlar mevcuttur.Bu sebepten dolayı orak hücre hastalarında covid-19 enfeksiyon seyrini göstermeyi hedefledik. Gereç ve Yöntem:Çalışmamız covid-19 ile enfekte olan erişkin yaş grubundaki 21 orak hücre hastasının verilerinden oluşturulmuştur.Bu hastaların laboratuvar ve görüntüleme sonuçları incelenmiştir. Bulgular:Bu hastaların normal popülasyona göre mortalite oranlarının arttığını saptadık. Özellikle hastalık geçmişlerinin mortalite üzerinde etkili olduğunu düşünmekle beraber bazı labaratuvar parametrelerinin de ( CRP, Ferritin , D-Dimer ve LDH ) mortal seyreden hastalarda yüksek seyrettiğini gördük. Sonuç:Bu hasta grubundaki yüksek mortalite sebebiyle klinik ve labaratuvar olarak kötü gidişin olduğu hastalarda covid-19 enfeksiyon tedavilerine ek olarak transfüzyon tedavilerinin erken dönemde başlanması gerektiğini düşünmekteyiz.

Anahtar Kelimeler:

Orak hücre hastalığı, ohh, covid-19

Clinical Outcomes caused by COVİD-19 in patients with Sickle Cell Disease in the Hatay Province of Turkey

Objective:The covid-19 infection caused by the severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) can be mortal particularly due to respiratory system involvement and coagulopathy.On the other hand, respiratory system involvement and coagulopathy are among the major causes of mortality in sickle cell patients as well.There are conflicting results in the literature on the mortality rates caused by covid-19 infection in sickle cell patients.For this reason, we aimed to show the course of covid-19 infection in sickle cell patients. Method:Our study was created from the data of 21 sickle cell patients in the adult age group who were infected with covid-19.The laboratory and imaging results of these patients were reviewed. Result:İt was found that these patients had increased mortality rates compared to the normal population.It was concluded that mainly the medical histories of the patients were effective on the associated mortality rates, yet it was also observed that certain laboratory parameters (C-reactive Protein, Ferritin, D-Dimer and Lactate Dehydrogenase) were elevated in mortal patients. Conclusion:İt is recommended that the transfusion treatments be started early in patients with a poor clinical and laboratory prognosis due to the high mortality rate in this patient group, in addition to the treatments administered in relation to covid-19 infection.

Keywords:

Sickle cell dieases, sca, covid-19,

PDF

___

1. Huang, Chaolin et al. “Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506.
2. WHO Coronavirus (COVID-19) Dashboard Web site https://covid19.who.int/ (accessed March 2021).
3. Wu, Zunyou, and Jennifer M McGoogan. “Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239-1242.
4. Tisminetzky, Mayra et al. “Age, Multiple Chronic Conditions, and COVID-19: A literature review.J Gerontol A Biol Sci Med Sci. 2020;glaa320.
5. Harrison, Stephanie L et al. “Comorbidities associated with mortality in 31,461 adults with COVID-19 in the United States: A federated electronic medical record analysis. PLoS Med. 2020;17(9):e1003321.
6. Piel, Frédéric B et al. “Global distribution of the sickle cell gene and geographical confirmation of the malaria hypothesis. Nat Commun. 2010;1:104.
7. Abdulrahman, Abdulkarim et al. “Is sickle cell disease a risk factor for severe COVID-19 outcomes in hospitalized patients? A multicenter national retrospective cohort study.EJHaem. 2021;10.1002/jha2.170.
8. Lubeck, Deborah et al. “Estimated Life Expectancy and Income of Patients With Sickle Cell Disease Compared With Those Without Sickle Cell Disease. JAMA Netw Open. 2019;2(11):e1915374.
9. Paulukonis, Susan T et al. “Defining Sickle Cell Disease Mortality Using a Population-Based Surveillance System, 2004 through 2008. Public Health Rep. 2016;131(2):367-375.
10. van Tuijn, Charlotte F J et al. “Acute chest syndrome in sickle cell disease due to the new influenza A (H1N1) virus infection. Am J Hematol. 2010;85(4):303-304.
11. George, Alex et al. “The impact of the 2009 H1N1 influenza pandemic on pediatric patients with sickle cell disease.Pediatr Blood Cancer. 2011;57(4):648-653.
12. Wu, Chaomin et al. “Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med. 2020;180(7):934-943.
13. Beerkens, Frans et al. “COVID-19 pneumonia as a cause of acute chest syndrome in an adult sickle cell patient. Am J Hematol. 2020;95(7):E154-E156.
14. Nur, Erfan et al. “Vaso-occlusive crisis and acute chest syndrome in sickle cell disease due to 2019 novel coronavirus disease (COVID-19). Am J Hematol. 2020;95(6):725-726.
15. Hussain, Faiz A et al. “COVID-19 infection in patients with sickle cell disease. Br J Haematol. 2020;189(5):851-852.
16. AbdulRahman, Abdulkarim et al. “COVID-19 and sickle cell disease in Bahrain. Int J Infect Dis. 2020;101:14-16.
17. Panepinto, Julie A et al. “Coronavirus Disease among Persons with Sickle Cell Disease, United States, March 20-May 21, 2020. Emerg Infect Dis. 2020;26(10):2473-2476.
18. Arlet, Jean-Benoît et al. “Prognosis of patients with sickle cell disease and COVID-19: a French experience. Lancet Haematol. 2020;7(9):e632-e634.
19. Balanchivadze, Nino et al. “Impact of COVID-19 Infection on 24 Patients with Sickle Cell Disease. One Center Urban Experience, Detroit, MI, USA. Hemoglobin. 2020;44(4):284-289.
20. CDC COVID-19 Response Team. “Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) - United States, February 12-March 16, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(12):343-346.
21. Pinto VM, Balocco M, Quintino S, Forni GL. Sickle cell disease: a review for the internist. Intern Emerg Med. 2019;14(7):1051-1064.
22. Allison, David et al. “Red blood cell exchange to avoid intubating a COVID-19 positive patient with sickle cell disease?. J Clin Apher. 2020;35(4):378-381.
23. De Luna, Gonzalo et al. “Rapid and severe Covid-19 pneumonia with severe acute chest syndrome in a sickle cell patient successfully treated with tocilizumab. Am J Hematol. 2020;95(7):876-878.
24. Naik RP, Streiff MB, Haywood C Jr, Nelson JA, Lanzkron S. Venous thromboembolism in adults with sickle cell disease: a serious and under-recognized complication. Am J Med. 2013;126(5):443-449.
25. Kollias, Anastasios et al. “Thromboembolic risk and anticoagulant therapy in COVID-19 patients: emerging evidence and call for action. Br J Haematol. 2020;189(5):846-847.
26. Tang, Ning et al. “Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020;18(5):1094-1099.
27. Alsayegh, Faisal, and Shaker A Mousa. “Challenges in the Management of Sickle Cell Disease During SARS-CoV-2 Pandemic. Clin Appl Thromb Hemost. 2020;26:1076029620955240.